Literature DB >> 2045203

Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators.

P Nygren1, R Larsson.   

Abstract

The intrinsically Vincristine(Vcr)-resistant human kidney adenocarcinoma cell line ACHN, the human acute lymphoblastic leukemia cell line L0, its more-than-100-fold Vcr-resistant subline LI00, normal human fibroblasts and lymphocytes, also tumor cells from patients with chronic lymphocytic leukemia (CLL), acute myeloblastic leukemia (AML) and solid tumors, were compared for sensitivity to cytotoxic drugs and resistance modulators (RMs). The LI00 cells showed pronounced sensitivity to the RMs verapamil (Ver), cyclosporin A (CsA) and buthionine sulfoximine (BSO) alone as well as to cisplatinum, whereas the L0 and ACHN cells, also slowly growing fibroblasts and non-proliferating lymphocytes, were considerably less sensitive. Compared with AML cells and lymphocytes, CLL cells were more sensitive to Ver and CsA alone. The cytotoxicity of Vcr was significantly increased in the Vcr-resistant ACHN and LI00, but also in sensitive L0 cells by Ver and CsA, with smaller effects on Dox and Vp-16 toxicity. Fibroblasts and lymphocytes were generally resistant to the cytotoxic agents and RM addition had only minor effects. CLL cells were more sensitive to Dox and Vcr as compared with normal lymphocytes, with potentiation of the Vcr effect by Ver and CsA. The Vcr effect in non-proliferating Vcr-resistant cells from a malignant schwannoma was potentiated by Ver and CsA, which had no effect in cells from a kidney adenocarcinoma. We conclude that cytotoxicity of RMs alone is not dependent on the proliferation rate of tumor cells and that potentiation of cytotoxic drugs by RMs may be selective for tumor cells irrespective of their initial level and mode of drug resistance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2045203     DOI: 10.1002/ijc.2910480419

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Differential effectiveness of a range of novel drug-resistance modulators, relative to verapamil, in influencing vinblastine or teniposide cytotoxicity in human lymphoblastoid CCRF-CEM sublines expressing classic or atypical multidrug resistance.

Authors:  B T Hill; L K Hosking
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  Potential therapeutic implications of intracrine angiogenesis.

Authors:  Richard N Re; Julia L Cook
Journal:  Med Hypotheses       Date:  2007-02-22       Impact factor: 1.538

3.  In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia.

Authors:  J Kristensen; B Jonsson; C Sundström; P Nygren; R Larsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

4.  Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.

Authors:  Joachim Gullbo; Elin Lindhagen; Saadia Bashir-Hassan; Marcus Tullberg; Hans Ehrsson; Rolf Lewensohn; Peter Nygren; Manuel De La Torre; Kristina Luthman; Rolf Larsson
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

5.  Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression.

Authors:  P Nygren; R Larsson; A Gruber; C Peterson; J Bergh
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

6.  Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.

Authors:  S Dhar; P Nygren; K Csoka; J Botling; K Nilsson; R Larsson
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

7.  RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma.

Authors:  B A Wilky; C Kim; G McCarty; E A Montgomery; K Kammers; L R DeVine; R N Cole; V Raman; D M Loeb
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

8.  Activity of cyclosporins as resistance modifiers in primary cultures of human haematological and solid tumours.

Authors:  H Fridborg; B Jonsson; P Nygren; K Csoka; K Nilsson; G Oberg; J Kristensen; J Bergh; B Tholander; L Olsen
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

9.  Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles.

Authors:  L Rickardson; M Fryknäs; S Dhar; H Lövborg; J Gullbo; M Rydåker; P Nygren; M G Gustafsson; R Larsson; A Isaksson
Journal:  Br J Cancer       Date:  2005-08-22       Impact factor: 7.640

10.  Mesenchymal stem cells maintain their defining stem cell characteristics after treatment with cisplatin.

Authors:  Nils H Nicolay; Ramon Lopez Perez; Alexander Rühle; Thuy Trinh; Sonevisay Sisombath; Klaus-Josef Weber; Anthony D Ho; Jürgen Debus; Rainer Saffrich; Peter E Huber
Journal:  Sci Rep       Date:  2016-01-25       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.